NovoCure Ltd (FRA:038)
€ 16.225 -0.425 (-2.55%) Market Cap: 1.75 Bil Enterprise Value: 1.48 Bil PE Ratio: 0 PB Ratio: 5.23 GF Score: 69/100

Novocure Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 01:20PM GMT
Release Date Price: €144.4 (+4.30%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good morning from the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap Biotech Analyst, and it's my pleasure to introduce our next company, NovoCure, and Executive Chairman, Bill Doyle.

Please note that following this presentation, we will have a Q&A session where you have the ability to submit questions via the little blue, ask-a-question button in your conference portal. So with that, Bill, thanks for being here today, and let me turn things over to you.

William F. Doyle
NovoCure Limited - Executive Chairman

Hello, Cory. Good morning. I'm joining you from NovoCure's operations center in Portsmouth, New Hampshire. And I want to say hello to everybody. Good morning to everyone in the U.S., and hello to everyone in the rest of the world.

I'm going to call out the numbers of the slides that I'm going to be presenting this morning, so that everyone can follow along. I'll start with Slide 2. I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot